172 related articles for article (PubMed ID: 1881637)
1. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: partial protection against striato-nigral dopamine depletion in C57BL/6J mice by cigarette smoke exposure and by beta-naphthoflavone-pretreatment.
Shahi GS; Das NP; Moochhala SM
Neurosci Lett; 1991 Jun; 127(2):247-50. PubMed ID: 1881637
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by tobacco smoke.
Carr LA; Rowell PP
Neuropharmacology; 1990 Mar; 29(3):311-4. PubMed ID: 2325834
[TBL] [Abstract][Full Text] [Related]
3. PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice.
Perez V; Unzeta M
Neurochem Int; 2003 Feb; 42(3):221-9. PubMed ID: 12427476
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain.
Fuller RW; Robertson DW; Hemrick-Luecke SK
J Pharmacol Exp Ther; 1987 Feb; 240(2):415-20. PubMed ID: 3100775
[TBL] [Abstract][Full Text] [Related]
5. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor.
Sagi Y; Weinstock M; Youdim MB
J Neurochem; 2003 Jul; 86(2):290-7. PubMed ID: 12871570
[TBL] [Abstract][Full Text] [Related]
6. Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B.
Finnegan KT; Irwin I; Delanney LE; Langston JW
J Pharmacol Exp Ther; 1995 May; 273(2):716-20. PubMed ID: 7752075
[TBL] [Abstract][Full Text] [Related]
7. Influence of selective, reversible inhibitors of monoamine oxidase on the prolonged depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Fuller RW; Hemrick-Luecke SK
Life Sci; 1985 Sep; 37(12):1089-96. PubMed ID: 3875779
[TBL] [Abstract][Full Text] [Related]
8. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Gal S; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
[TBL] [Abstract][Full Text] [Related]
9. Partial protective effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice.
Tabatabaei A; Perry TL; Hansen S; Krieger C
Neurosci Lett; 1992 Jul; 141(2):192-4. PubMed ID: 1436633
[TBL] [Abstract][Full Text] [Related]
10. Apomorphine protects against MPTP-induced neurotoxicity in mice.
Grünblatt E; Mandel S; Berkuzki T; Youdim MB
Mov Disord; 1999 Jul; 14(4):612-8. PubMed ID: 10435498
[TBL] [Abstract][Full Text] [Related]
11. Exposure to cigarette smoke does not decrease the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Perry TL; Hansen S; Jones K
Neurosci Lett; 1987 Feb; 74(2):217-20. PubMed ID: 3494963
[TBL] [Abstract][Full Text] [Related]
12. Neurochemical evidence for agmatine modulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity.
Gilad GM; Gilad VH; Finberg JP; Rabey JM
Neurochem Res; 2005; 30(6-7):713-9. PubMed ID: 16187208
[TBL] [Abstract][Full Text] [Related]
13. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
14. Effects of tobacco smoke constituents on MPTP-induced toxicity and monoamine oxidase activity in the mouse brain.
Carr LA; Basham JK
Life Sci; 1991; 48(12):1173-7. PubMed ID: 2002748
[TBL] [Abstract][Full Text] [Related]
15. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment.
Irwin I; Finnegan KT; Delanney LE; Di Monte D; Langston JW
Brain Res; 1992 Feb; 572(1-2):224-31. PubMed ID: 1611516
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity.
Wu WR; Zhu XZ; Guan HJ; Wang RG; Ji XQ
Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):146-50. PubMed ID: 10437162
[TBL] [Abstract][Full Text] [Related]
17. Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me-MPTP.
Kindt MV; Youngster SK; Sonsalla PK; Duvoisin RC; Heikkila RE
Eur J Pharmacol; 1988 Feb; 146(2-3):313-8. PubMed ID: 3131149
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective aspects of a novel MAO-B inhibitor PF9601N.
Pérez V; Morón J; Pastó M; Unzeta M
Neurobiology (Bp); 2000; 8(3-4):231-6. PubMed ID: 11225513
[TBL] [Abstract][Full Text] [Related]
19. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.
Grünblatt E; Mandel S; Maor G; Youdim MB
J Neurochem; 2001 Apr; 77(1):146-56. PubMed ID: 11279270
[TBL] [Abstract][Full Text] [Related]
20. Effect of chronic oral nicotine on dopaminergic function in the MPTP-treated mouse.
Sershen H; Hashim A; Wiener HL; Lajtha A
Neurosci Lett; 1988 Nov; 93(2-3):270-4. PubMed ID: 3266524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
